Rituximab +/- Bevacizumab in the Treatment of Patients With Follicular Non-Hodgkin's Lymphoma: A Randomized, Phase II Trial.

Trial Profile

Rituximab +/- Bevacizumab in the Treatment of Patients With Follicular Non-Hodgkin's Lymphoma: A Randomized, Phase II Trial.

Discontinued
Phase of Trial: Phase II

Latest Information Update: 10 Jan 2015

At a glance

  • Drugs Bevacizumab (Primary) ; Rituximab
  • Indications Follicular lymphoma
  • Focus Therapeutic Use
  • Most Recent Events

    • 01 Aug 2014 Interim results published in the Clinical Lymphoma, Myeloma & Leukemia.
    • 13 Feb 2014 Planned End Date changed from 1 Dec 2013 to 1 Jun 2014, as per ClinicalTrials.gov record.
    • 10 Dec 2012 Results presented at the 54th Annual Meeting and Exposition of the American Society of Hematology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top